Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIT565 phase Ib open-label ascending-dose study in rheumatoid arthritis
NL-OMON60556Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PIT565 in rheumatoid arthritis (RA), sponsored by Novartis. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
PIT565
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON60556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60556.